Sorry to hear it didn't work for you Karin...
Statistically it works for most (but not all) KRAS-wt patients. Whys doesn't it work in a subset of patients? I think this comes down to cancer being an incredibly complex & personalized disease which the current simplistic KRAS tests can not model accurately. It is clear that if you come back KRAS-mut, you have essentially zero chance of having benefit from cetuximab - in contrast KRAS-wt means that you are "likely" to achieve benefit but since it is a simplistic test - there are false positives in terms of recommending anti-EGFR treatment - which sounds like it happened in you case. Hopefully there will be more accurate screening methods in the near future.
There was a recent paper describing mutations which make a patient resistant to cetuximab. https://clincancerres.aacrjournals.org/ ... 7.abstract
Although they are talking about acquired resistance, there is no reason to assume that at least some of these mutations (which would not be uncovered by the currently simple KRAS test) couldn't be pre-existing in some patients. Still other patients significantly upregulate EGF as a non-genetic strategy to be resistant to cetuximab.
Statistically, since they are dosing Sym004 only to the majority of KRAS-wt patients who did respond to cetuximab, as a follow up therapy, it is likely to work in most of that patient population.
Once again I am sorry it was not a successful strategy for you...
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List